Novartis $23bn US Investment Is Music To Trump’s Ears

The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.

Novartis RLT manufacturing facility in Indianapolis

As Donald Trump’s threats to impose tariffs on imported pharmaceuticals increase in intensity, the US president will be pleased to hear that Novartis is expanding its manufacturing and R&D footprint in the country with a total investment of $23bn over the next five years.

Key Takeaways
  • Novartis says the huge investment means it will produce “100% of its key medicines end-to-end in the US, a significant increase from current levels”

The Switzerland-headquartered giant said that the investment included a newly planned $1.1bn R&D hub in San Diego, CA, which is expected to open between 2028 and 2029

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Advanced Therapies

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By 

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.